Matches in SemOpenAlex for { <https://semopenalex.org/work/W2758403321> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2758403321 endingPage "204" @default.
- W2758403321 startingPage "195" @default.
- W2758403321 abstract "Atovaquone in combination with proguanil hydrochloride, marketed as Malarone® tablets by GlaxoSmithKline (GSK), is prescribed for the treatment of malaria. High dose and poor bioavailability are the main hurdles associated with atovaquone oral therapy. The present study reports development of atovaquone nanoparticles, using in house designed and fabricated electrospraying equipment, and the assessment of bioavailability and therapeutic efficacy of the nanoparticles after oral administration. Solid nanoparticles of atovaquone were successfully produced by electrospraying and were characterized for particle size and flow properties. Differential Scanning Calorimetry, X-ray Diffraction, Fourier Transform Infrared Spectroscopy studies were also carried out. Atovaquone nanoparticles along with proguanil hydrochloride and a suitable wetting agent were filled in size 2 hard gelatin capsules. The formulation was compared with Malarone® tablets (GSK) and Mepron® suspension (GSK) in terms of in vitro release profile and in vivo pharmacokinetic studies. It showed 2.9-fold and 1.8-fold improved bioavailability in rats compared to Malarone® tablets and Mepron® suspension respectively. Therapeutic efficacy of the formulation was determined using modified Peter's 4-day suppressive tests and clinical simulation studies using Plasmodium berghei ANKA infected Swiss mice and compared to Malarone®. The developed formulation showed a 128-fold dose reduction in the modified Peter's 4-day suppressive tests and 32-fold dose reduction in clinical simulation studies. Given that only one capsule a day of developed formulation is required to be administered orally compared to 4 Malarone® tablets once a day and that too at a significantly reduced dose, this nanoparticle formulation will definitely reduce the side-effects of the treatment and is also likely to increase patient compliance." @default.
- W2758403321 created "2017-10-06" @default.
- W2758403321 creator A5007769890 @default.
- W2758403321 creator A5060656461 @default.
- W2758403321 creator A5068323156 @default.
- W2758403321 creator A5075868662 @default.
- W2758403321 date "2018-01-01" @default.
- W2758403321 modified "2023-10-01" @default.
- W2758403321 title "Atovaquone oral bioavailability enhancement using electrospraying technology" @default.
- W2758403321 cites W1603093745 @default.
- W2758403321 cites W1985305655 @default.
- W2758403321 cites W2004164069 @default.
- W2758403321 cites W2009082036 @default.
- W2758403321 cites W2036344359 @default.
- W2758403321 cites W2047393407 @default.
- W2758403321 cites W2089337157 @default.
- W2758403321 cites W2105502591 @default.
- W2758403321 cites W2128204697 @default.
- W2758403321 cites W2474928846 @default.
- W2758403321 cites W2552801722 @default.
- W2758403321 cites W70108856 @default.
- W2758403321 doi "https://doi.org/10.1016/j.ejps.2017.09.051" @default.
- W2758403321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28974387" @default.
- W2758403321 hasPublicationYear "2018" @default.
- W2758403321 type Work @default.
- W2758403321 sameAs 2758403321 @default.
- W2758403321 citedByCount "15" @default.
- W2758403321 countsByYear W27584033212019 @default.
- W2758403321 countsByYear W27584033212020 @default.
- W2758403321 countsByYear W27584033212021 @default.
- W2758403321 countsByYear W27584033212022 @default.
- W2758403321 countsByYear W27584033212023 @default.
- W2758403321 crossrefType "journal-article" @default.
- W2758403321 hasAuthorship W2758403321A5007769890 @default.
- W2758403321 hasAuthorship W2758403321A5060656461 @default.
- W2758403321 hasAuthorship W2758403321A5068323156 @default.
- W2758403321 hasAuthorship W2758403321A5075868662 @default.
- W2758403321 hasConcept C112705442 @default.
- W2758403321 hasConcept C181389837 @default.
- W2758403321 hasConcept C185592680 @default.
- W2758403321 hasConcept C192562407 @default.
- W2758403321 hasConcept C203014093 @default.
- W2758403321 hasConcept C2778048844 @default.
- W2758403321 hasConcept C2778371730 @default.
- W2758403321 hasConcept C2778778583 @default.
- W2758403321 hasConcept C2779124865 @default.
- W2758403321 hasConcept C43617362 @default.
- W2758403321 hasConcept C59822182 @default.
- W2758403321 hasConcept C71924100 @default.
- W2758403321 hasConcept C86803240 @default.
- W2758403321 hasConcept C98274493 @default.
- W2758403321 hasConceptScore W2758403321C112705442 @default.
- W2758403321 hasConceptScore W2758403321C181389837 @default.
- W2758403321 hasConceptScore W2758403321C185592680 @default.
- W2758403321 hasConceptScore W2758403321C192562407 @default.
- W2758403321 hasConceptScore W2758403321C203014093 @default.
- W2758403321 hasConceptScore W2758403321C2778048844 @default.
- W2758403321 hasConceptScore W2758403321C2778371730 @default.
- W2758403321 hasConceptScore W2758403321C2778778583 @default.
- W2758403321 hasConceptScore W2758403321C2779124865 @default.
- W2758403321 hasConceptScore W2758403321C43617362 @default.
- W2758403321 hasConceptScore W2758403321C59822182 @default.
- W2758403321 hasConceptScore W2758403321C71924100 @default.
- W2758403321 hasConceptScore W2758403321C86803240 @default.
- W2758403321 hasConceptScore W2758403321C98274493 @default.
- W2758403321 hasLocation W27584033211 @default.
- W2758403321 hasLocation W27584033212 @default.
- W2758403321 hasOpenAccess W2758403321 @default.
- W2758403321 hasPrimaryLocation W27584033211 @default.
- W2758403321 hasRelatedWork W2080955156 @default.
- W2758403321 hasRelatedWork W2348235863 @default.
- W2758403321 hasRelatedWork W2359945451 @default.
- W2758403321 hasRelatedWork W2360661184 @default.
- W2758403321 hasRelatedWork W2378952652 @default.
- W2758403321 hasRelatedWork W2380630615 @default.
- W2758403321 hasRelatedWork W2387882446 @default.
- W2758403321 hasRelatedWork W2392867183 @default.
- W2758403321 hasRelatedWork W2394170919 @default.
- W2758403321 hasRelatedWork W2899084033 @default.
- W2758403321 hasVolume "111" @default.
- W2758403321 isParatext "false" @default.
- W2758403321 isRetracted "false" @default.
- W2758403321 magId "2758403321" @default.
- W2758403321 workType "article" @default.